3SBio Will Market Eli Lilly's Recombinant Insulin In China

3SBio of Shenyang entered a strategic cooperation agreement with Lilly China under which 3SBio will promote and distribute Lilly's well-established Humulin®, an insulin product. Originally formulated in 1982, Humulin was the first recombinant insulin product in the world. It has been available in China since 1997. In October 2016, 3SBio paid $100 million for rights to market two AstraZeneca diabetes products in China: Byetta and Bydureon, both of which are injectable Glucagon-Like Peptide-1 antagonists for type 2 diabetes.

Back to news